Healthy Volunteers
Conditions
Keywords
Cognitive function, Omega-3 fatty acids, Alpha-linolenic acid, EPA, DHA, Oxidative stress, Tensiomyography, Body composition, Neuromuscular function
Brief summary
Therefore, the aim of our project will be to assess the impact of omega-3 fatty acid on the neuromuscular system (muscle tensomyography- TMG), the composition and fluidity of erythrocyte cell membranes, the lipid profile and the antioxidant status of the blood.
Detailed description
The ability of skeletal muscles to generate force and resist fatigue is essential for athletic performance. Training adaptations within the neuromuscular system and skeletal muscles modulate the muscles' ability to produce force and resistance to fatigue. Much research has been conducted to determine the effects of dietary supplements on skeletal muscle adaptation to strength training (e.g., protein supplementation) and methods to support endurance performance (e.g., carbohydrate loading). However, limited research has been conducted to date on the effects of dietary supplements on the neuromuscular system.The research will focus on the effect of 4 and 8 weeks of supplementation with high doses of omega 3 fatty acids on the level of omega 3/omega6 fatty acids, the level of TRANS fatty acids and AA (arachidonic acid) fatty acid using a mixed diet. Additionally, we will examine the effect of this supplementation on the neuromuscular system (muscle tensomyography -TMG), the composition and fluidity of erythrocyte cell membranes, the lipid profile and the antioxidant status of the blood. The research will use innovative assumptions - high doses of omega 3 fatty acids. Additionally, a new laboratory tool will be used to assess the level of individual fatty acids (omega 3, omega 6) in the blood, the level of which shows or excludes latent inflammation in the body.
Interventions
DIETARY_SUPPLEMENTEPA/DHA supplements
The supplement will be administered in a dose of 4 capsules twice a day for 4 weeks. Each capsule will contain 330mg EPA and 220mgDHA.
DIETARY_SUPPLEMENTALA supplements
The supplement will be administered in a dose of 4 capsules twice a day for 4 weeks. Daily dose will contain 3500mg ALA.
DIETARY_SUPPLEMENTPlacebo supplements
The supplement will be administered in a dose of 4 capsules twice a day for 4 weeks. One capsule will contain 550 mg of olive oil. The placebo will be matched to the supplement in appearance.
Sponsors
The Jerzy Kukuczka Academy of Physical Education in Katowice
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
The participants will be randomly assigned to 4 groups: a group supplemented with EPA+DHA (eicosapentaenoic + docosahexaenoic fatty acids) (animal source), a group supplemented with ALA (apha-linolenic) fatty acids (plant source), a placebo supplemented control group, and a control group without supplementation. After 4 weeks of supplementation, there will be a 3 month washout period. After the 3 month break, the second stage will begin, which will also last 4 weeks, during which the groups will be crossed over.
Eligibility
Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
\*\*Inclusion Criteria:\*\* * Male participants aged 20-40 years. * Apparently healthy individuals, as determined by medical history and self-reported health status. * Physically active, engaging in regular physical activity at least 3 times per week for the previous 6 months. * Following a mixed diet. * Willingness to maintain habitual dietary and physical activity patterns throughout the study. * Willingness to refrain from consuming dietary supplements other than those provided as part of the study. \*\*
Exclusion criteria
\*\* * Current use of dietary supplements within 4 weeks prior to enrollment. * Following a low-carbohydrate, ketogenic, high-carbohydrate, vegetarian, or vegan diet. * Presence of gastrointestinal disorders affecting nutrient absorption, including irritable bowel syndrome, inflammatory bowel disease, celiac disease, or other clinically significant gastrointestinal conditions. * History of cardiovascular, metabolic, endocrine, hepatic, renal, neurological, or autoimmune diseases. * Current use of medications known to affect lipid metabolism, inflammation, antioxidant status, or cognitive function. * Known allergy or intolerance to study supplements or their ingredients. * Participation in another clinical trial within the previous 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Omega 3 index | 4-weeks | The Omega-3 Index (%) determines the content of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) relative to total fatty acids in erythrocyte membranes. It is expressed as a percentage and reflects long-term fatty acid intake. Unit of Measure: % |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tensiomyography (TMG) Parameters | 4-weeks | 2a. Maximal Radial Displacement (Dm) Unit of Measure: mm 2b. Contraction Time (Tc) Unit of Measure: ms 2c. Delay Time (Td) Unit of Measure: ms 2d. Sustain Time (Ts) Unit of Measure: ms 2e. Half-Relaxation Time (Tr) Unit of Measure: ms Description: Muscle contractile properties assessed using tensiomyography (TMG-BMC system). |
| Corsi Block-Tapping Test - Unweighted Block Span | 4-weeks | Description: Maximum correctly reproduced sequence length in Corsi Block-Tapping Test. Unit of Measure: blocks |
| Corsi Block-Tapping Test - Block Time | 4 weeks | Description: Reaction time performance in visuospatial working memory assessed using Corsi Block-Tapping Test. Unit of Measure: ms |
| Corsi Block-Tapping Test - Reverse Span Score | 4 weeks | Description: Working memory performance assessed using reverse span condition of Corsi Block-Tapping Test. Unit of Measure: score |
Countries
Poland
Contacts
STUDY_DIRECTORMałgorzata Magdalena Michalczyk, Phd
Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice
Outcome results
None listed